Decreased expression of endometrial decay accelerating factor (DAF), a complement regulatory protein, in patients with luteal phase defect.
OBJECTIVE
We investigated the level of decay accelerating factor (DAF) in the endometrium of luteal phase defect (LPD) patients, before and after treatment with progesterone.


METHODS
Endometrial samples from fourteen normal-cycling controls and six samples from infertility patients with LPD before and four samples after progesterone treatment were stained by anti-DAF IgG using immunohistochemistry.


RESULTS
Mean DAF OD in LPD patients was 15% compared to 60% in the control group. The mean DAF OD was 88% after treatment with progesterone.


CONCLUSIONS
Results support interpretation that progesterone upregulates DAF while decreased progesterone may be associated with reduced expression of the DAF in LPD patients.
Kaul
A
A
Department of Obstetrics & Gynecology, University of Texas Medical Branch at Galveston 77555-1062, USA.
Nagamani
M
M
Nowicki
B
B
D000328:Adult; D018958:CD55 Antigens / Q000096:biosynthesis* / Q000187:drug effects / Q000276:immunology; D003167:Complement Activation; D004717:Endometrium / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007247:Infertility, Female / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D008183:Luteal Phase / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D011374:Progesterone / Q000627:therapeutic use
D018958:CD55 Antigens; D011374:Progesterone